Pharmaceutical Research
&
Innovations in Pharma Industry

Alzheimer’s disease (AD) is a chronic neurodegenera ve disease among the top most common agerelated forms of demen a. Unfortunately, no current treatments are known to stop or reverse the progression of AD, though those in clinical use only temporarily improve symptoms. Consequently, the research society is in need of discovery of new biologically ac ve molecules that can contribute to the control of AD. Hallmarks of AD include accumula on of amyloid-β (Aβ) protein and neurofi brillary tangles (NFTs). GSK-3β is a validated key player in the development of Aβ and NFTs palying a crucial role in disease progression. Thus, it presents a valid target for new an -AD drug’s development. This research work displays the results of design and discovery of new oxadiazole scaff old based molecules with ATP-compe  ve GSK-3β inhibitory ac vity. Biological screening results of these new molecules show a promising ac vity profi le for these new en  es and pave the way for future development and op miza on of those discovered leads. Molecular modeling studies were also performed to stand on postulated binding modes of these chemotypes to the ATP binding site of GSK-3β.